AsianScientist (Nov. 12, 2014) – GE Healthcare and Takeda Pharmaceutical Company have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases.
Liver disease has almost no visible symptoms and its progress is characterized by a hardening of the tissues due to fibrosis accompanying the inflammation of the liver and a worsening of symptoms due to cirrhosis. Amid such worldwide trends of recent years as the aging population and less healthy lifestyle habits, non-alcoholic fatty liver disease (NAFLD) has emerged as a type of metabolic syndrome.
Over the past couple of decades, NAFLD and non-alcoholic steatohepatitis (NASH) have become the number one cause of liver disease in developed countries. The prevalence of NAFLD has doubled during the last 20 years, whereas the prevalence of other chronic liver diseases has remained stable or even decreased. Early diagnosis of hepatic fibrosis as well as the development of drugs to control the progression of liver disease have become important issues.
According to the alliance agreement, GE Healthcare will provide Takeda with its diagnostic imaging technology for use to generate a liver stiffness map as part of the research and development work Takeda is conducting on liver diseases. By optimizing the strengths of both companies in the alliance, the collaborative effort aims to help develop therapeutic drugs as well as new diagnostic technologies for liver diseases.
“This alliance will assist efforts to develop new therapeutic options that ease the burden on the patient,” said Dr. Tadataka Yamada, Chief Medical & Scientific Officer at Takeda.
Currently, the diagnosis of hepatic fibrosis is most commonly conducted by a liver biopsy, in which a needle is inserted through the skin into the liver, a sample of which is then removed for measurement. With MR elastography commercialized by GE Healthcare—in use in the United States since 2009 and in Japan since 2012—it has become possible to measure the relative stiffness of liver tissues in a non-invasive manner.
“It is extremely gratifying to me that, through this collaboration, our technologies will be of use in the development of treatments for the liver diseases that are of particular importance not just in Asia, but worldwide,” said Mr. Akihiko Kumagai, Chairman of GE Healthcare Japan with overall responsibility for liver disease programs.
——
Source: GE Healthcare.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
